IGF2BP3 and hepatocellular carcinoma: Similarly, IGF2BP3 overexpression de-sensitized sorafenib and doxorubicin by enhancing cancer stem cell marker CD133 and drug efflux proteins such as ABCB1 and ABCG2 in human hepatocellular carcinoma.